Tandem Therapeutics AG

Unlocking the matrix barrier in fibrotic diseases.

Swiss Startup - Tandem Therapeutics Main Image

Swiss Startup - Tandem Therapeutics Team Image

Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells. Presence of excessive matrix proteins are linked to therapeutic resistance and poor patient outcomes in fibrotic tumors and organ fibrosis. The matrix offers druggable biological real-estate to targets nodes that drive disease progression. At Tandem Therapeutics our goal is to precision target this barrier and bring drugs to this disease extracellular matrix thereby enhancing safety and efficacy. Using evolutionarily optimised peptides, we are decoding complex matrix-disease biology to create breakthrough solutions for patients burdened with fibrotic diseases.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

17.09.2024

The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)

20.06.2024

Sustainable start-ups excel at the W.A de Vigier Award (startupticker.ch)

19.04.2024

Wyss Zurich expands portfolio (startupticker.ch)

15.04.2024

Tandem Therapeutics joins Wyss Zurich Translational Center to accelerate progress in fibrosis treatment (venturelab.swiss)

04.04.2024

The top 15 startups in de Vigier Award revealed (startupticker.ch)

04.07.2023

Venture Leaders Biotech 2023: Captain’s Blog by Navignostics, Mosanna Therapeutics, Limula, and Tandem Therapeutics (venturelab.swiss)

19.06.2023

The Venture Leaders Biotech set sail on the Boston roadshow with immersive expert workshops, uniting entrepreneurs and investors in the US market (venturelab.swiss)

19.05.2023

Tandem Therapeutics: The Venture Leader Biotech focusing on precision targeting the extracellular matrix barrier in fibrotic cancers (venturelab.swiss)

25.04.2023

Venture Leaders Biotech kick off their Boston roadshow at Swiss Biotech Day (venturelab.swiss)

19.04.2023

Swiss National Startup Team 2023: 10 biotech innovators are headed to Boston (venturelab.swiss)

24.02.2023

Tandem Therapeutics wins CHF 150,000 to advance fight against fibrotic cancer (venturekick.ch)

10.08.2022

CHF 40,000 for rebuilding coral reefs, making sustainable fishing bait, and targeting diseased microenvironment in fibrosis (venturekick.ch)

19.06.2024

Dr. Mamta Chabria, CEO Tandem Therapeutics AG wins the 2024 W.A. de Vigier Award

01.04.2024

Tandem Therapeutics accepted into the Wyss Zurich Translational Center as Project TANDEM

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

TOP 100 Swiss Startups 2025 TOP 100 Swiss Startups 2024

Website

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2023

Website